New research and data presented at upcoming medical conferences suggest advancements in the treatment of allergies and related inflammatory conditions. Regeneron Pharmaceuticals, in collaboration with Sanofi, is set to present findings at the – , 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania.
Novel Approaches to Allergy Treatment
Regeneron will highlight 36 abstracts detailing its immunology and inflammation portfolio, with a particular focus on innovative Phase 3 programs targeting specific allergens. These programs aim to address the debilitating ocular symptoms experienced by adults with cat and birch allergies. The approach involves antibody cocktails designed to target major allergens – FelD1 for cat allergy and BetV1 for birch allergy – with the goal of reducing allergic reactions like itching and conjunctival redness following allergen exposure.
Initial trials have demonstrated the potential of these cocktails to reduce nasal, respiratory, and skin symptoms. Further registration trials, evaluating similar criteria over a longer period, are planned to begin this year. These programs represent a broader effort to develop strategies for eliminating IgE-mediated allergies, a significant step forward in allergy management.
Dupixent®: Expanding Applications and Long-Term Effects
Data concerning Dupixent® (dupilumab) will also be presented in collaboration with Sanofi. New analyses will focus on the drug’s impact across dermatological, respiratory, and gastrointestinal diseases. Specifically, researchers will present long-term data from an open-label Phase 3 extension study involving children with moderate to severe atopic dermatitis. This analysis measured IgE levels for common food and environmental allergens over a period of up to 1.5 years, including cow’s milk, wheat, house dust mite, and various plant and fungal allergens.
The research aims to understand the potential for early and prolonged treatment with Dupixent to influence allergic sensitization in children. This is a crucial area of investigation, as early intervention can potentially alter the course of allergic disease development.
Asthma Management and Dupixent
For adults and adolescents with asthma, real-world analyses will evaluate the benefits of introducing Dupixent earlier in the treatment strategy. These analyses will measure reductions in asthma exacerbations and systemic corticosteroid use in patients whose asthma is not adequately controlled with mid-dose inhaled corticosteroids (ICS). The study will compare the addition of Dupixent to either stepping up to high-dose ICS or adding other biologic therapies.
These findings could inform clinical practice guidelines and potentially lead to more effective asthma management strategies, reducing the reliance on higher doses of corticosteroids, which can have significant side effects.
Allergic Fungal Rhinosinusitis Breakthrough
Recent data, presented in November 2025, highlighted a significant advancement in the treatment of allergic fungal rhinosinusitis (AFRS). A pivotal Phase 3 study of Dupixent in adults and children aged 6 years and older with AFRS met both primary and secondary endpoints, demonstrating a reduction in signs and symptoms of the disease, including sinus opacification, nasal congestion, and nasal polyps, compared to placebo.
The U.S. Food and Drug Administration (FDA) accepted the supplemental biologics license application (sBLA) for Dupixent for this indication with a target action date of . If approved, Dupixent would be the first and only medicine specifically indicated for AFRS, representing a major step forward for patients suffering from this chronic inflammatory condition.
Expanding Immunology Portfolio
The presentations at AAAAI underscore Regeneron’s commitment to expanding its immunology portfolio and pipeline. The company’s focus on first-in-class allergy treatments and the broadening of Dupixent’s clinical evidence base, in collaboration with Sanofi, are key components of its long-term growth strategy. While earnings and revenue growth are currently in the high single to low double digits, the company is focused on converting its research and development efforts into new revenue streams.
The upcoming presentations at AAAAI, including the Phase 3 data on allergen-specific antibodies and new Dupixent analyses, reinforce the depth of Regeneron’s immunology platform. However, the immediate supports to the company’s investment story remain continued Dupixent execution, EYLEA HD adoption, and disciplined capital returns.
